54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
This study addresses part of the Terms of Reference for a scoping report ‘An analysis of approaches to laboratory capacity strengthening for drug resistant infections in low and middle income countries’. It has been produced as a separate report because it is also very relevant for a second stud...y ‘Supporting Surveillance Capacity for Antimicrobial Resistance: Regional Networks and Educational Resources’. This study compares antimicrobial surveillance systems in three low and middle income countries in order to describe the components of these systems and to understand which surveillance models are best suited to particular contexts. Ghana, Nigeria and Nepal were selected as study countries because they cover different continents and include one ‘fragile’ context (Nigeria). Brief information from Malawi is also included.
more
El documento, "Progreso en la prevención y el control de las enfermedades no transmisibles" (ENT), informa sobre los esfuerzos globales para reducir el impacto de las ENT, como las enfermedades cardíacas, el cáncer, la diabetes y las enfermedades respiratorias crónicas, siguiendo los compromisos... asumidos en reuniones de alto nivel de las Naciones Unidas. Destaca el progreso insuficiente para alcanzar las metas establecidas en el Objetivo de Desarrollo Sostenible 3.4, que busca reducir en un tercio la mortalidad prematura por ENT para 2030. Los desafíos clave incluyen la falta de financiamiento, la implementación limitada de intervenciones efectivas y barreras políticas y económicas, especialmente en países de bajos ingresos. El informe hace un llamado para fortalecer la cooperación internacional, reformar políticas y adoptar enfoques innovadores para cumplir con las metas de salud global.
more
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
Petersenet al.International Journal of Mental Health Systems2011,5:8http://www.ijmhs.com/content/5/1/8
Health Economics Review, 2016 6:7 -Published: 11 February 2016
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...demic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
more
Practical Guideline for collaborative interventions
Cureus 2024 Jan 16;16(1):e52358. doi: 10.7759/cureus.52358
Tuberculosis (TB) is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h...ave some familiarity with palliative care, so that general palliative care principles are available to all patients. The timely identification, and addressing, of adverse events occurring during the treatment course is considered as general palliative care for those receiving curative treatment. This publication summarizes the general palliative care approach, which is recommended for use in settings and services that occasionally treat palliative care patients, but do not provide palliative care as the main focus of their work. The review focuses on 18 high TB priority countries of the WHO European Region.
more
Operational Guidelines for Planning and Implementation in District Hospitals
ORIENTAÇÕES PRÁTICAS PARA INTERVENÇÕES COLABORATIVAS